Crescent Biopharma announces first patient dosed in ASCENT Phase 1/2 trial

Crescent Biopharma (CBIO) announced that the first patient has been dosed in its global ASCEND Phase 1/2 clinical trial evaluating CR-001, an investigational PD-1 x VEGF bispecific antibody, for the treatment of advanced solid tumors. “The initiation of ASCEND is a significant milestone for Crescent and the development of CR-001, which we believe has the potential to be a best-in-class therapy and immuno-oncology backbone,” said Ellie Im, M.D., chief medical officer of Crescent. “We are excited to be working with clinicians across the globe as we strive to improve the standard of care for people living with cancer. ASCEND is designed to comprehensively assess the clinical profile of CR-001, including its potential in both first-line and previously treated patients, and to generate a robust data set to drive our development strategy across multiple indications.”